Express News | Zhejiang Huahai Pharmaceutical: The first subject in New Zealand to be dosed with the TSLP/IL-11 bispecific monoclonal antibody independently developed by its subsidiary.

BreakingsDec 3 13:43

Express News | Zhejiang Huahai Pharmaceutical: Subsidiary HB56 injection granted clinical trial approval in New Zealand.

BreakingsOct 31 16:54

Aotec Pharma (688606) 2024 Third Quarterly Report Review: Small but excellent POCT leader, continuous improvement in operational situation.

Key Investment Events: On October 30, 2024, the company released its third-quarter report for 2024. In the third quarter alone, the company achieved revenue of 0.222 billion yuan, a year-on-year increase of 28.72%, with a net income attributable to shareholders of 0.74.

东吴证券Oct 31 00:00

Aotai Biotech: Third quarter report 2024

SZSIOct 31 00:00 · Announcements

Third Quarter Report 2024

SZSIOct 31 00:00 · Announcements

Aotec Biology (688606.SH) released its performance for the first three quarters, with net income of 0.198 billion yuan, a year-on-year increase of 94.48%.

Aotec Pharmaceuticals (688606.SH) disclosed the third quarter report for 2024, achieving revenue of 6....

Zhitong FinanceOct 30 20:57